Rabies immune globulin, human
Cat# : THP-0176
| Cat#: |
THP-0176 |
| Product Name: |
Rabies immune globulin, human |
| Description: |
Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system. |
| Sequences: |
Not Available |
| Species: |
Human |
| Molecular Weight: |
Not Available |
| Cas No: |
Not Available |
| Formula: |
Not Available |
| Endotoxin Level: |
<0.001 EU per 1 μg of the peptide by the LAL method |
| Biological Activity: |
150IU/ml |
| Drug Name: |
Human rabies virus immune globulin |
| Applications: |
For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine. |
| Examples of Clinical Use: |
Rabies virus |
| Pharmacodynamics: |
Rabies immune globulin prevents viral invasion of the central nervous system. |
| Mechanism of action: |
Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine. |
| Affected organisms: |
Not Available |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
